The news that Mozobil hit primary and secondary goals in a late-stage trial for non-Hodgkin's lymphoma. The drug spurs the release of bone marrow stem cells into the blood so that they can be collected and used in a transplant. About six in 10 of the patients in the study demonstrated an increased stem cell count while 87 percent produced the necessary number of stem cells needed for a transplant. Applications for U.S. and European marketing approval is now expected in the first half of next year. Genzyme gained Mozobil when it bought out AnorMED earlier this year.
Progress report for stem cell stury
- Thread starter lraynak
- Start date